Reflex testing of resected stage i through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center

Journal of Thoracic and Cardiovascular Surgery

Volumn 141, Issue 2, 2011, Pages 476-480

  D'Angelo, Sandra P ^a   Park, Bernard ^a   Azzoli, Christopher G ^a   Kris, Mark G ^a   Rusch, Valerie ^a   Ladanyi, Marc ^a   Zakowski, Maureen F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ARTICLE; CANCER STAGING; CANCER SURGERY; EXON; FEASIBILITY STUDY; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFLEX TESTING;

ADENOCARCINOMA; DNA MUTATIONAL ANALYSIS; EXONS; FEASIBILITY STUDIES; FEMALE; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; NEW YORK CITY; PATIENT SELECTION; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION;

EID: 78751578969     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2010.08.026     Document Type: Article

References (28)

1. P.M. Ravdin, and G. Davis Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables Lung Cancer 52 2006 207 212
2. R. Arriagada, B. Bergman, A. Dunant, T. Le Chevalier, J.P. Pignon, and J. Vansteenkiste Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
3. C.G. Azzoli, B.J. Park, W. Pao, M. Zakowski, and M.G. Kris Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise J Thorac Oncol 3 2008 84 93
4. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565
5. A.R. Li, D. Chitale, G.J. Riely, W. Pao, V.A. Miller, and M.F. Zakowski EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression J Mol Diagn 10 2008 242 248
6. G.J. Riely, W. Pao, D. Pham, A.R. Li, N. Rizvi, and E.S. Venkatraman Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib Clin Cancer Res 12 Pt 1 2006 839 844
7. A.F. Gazdar Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 28 Suppl 1 2009 S24 S31
8. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
9. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
10. E.K. Rowinsky, M. Jiroutek, P. Bonomi, D. Johnson, and S.D. Baker Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin Clin Cancer Res 5 1999 767 774
11. S.L. Graziano, G.P. Gamble, N.B. Newman, L.Z. Abbott, M. Rooney, and S. Mookherjee Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer J Clin Oncol 17 1999 668 675
12. S.A. Ahrendt, P.A. Decker, E.A. Alawi, Y.R. Zhu Yr, M. Sanchez-Cespedes, and S.C. Yang Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung Cancer 92 2001 1525 1530
13. C. Mascaux, N. Iannino, B. Martin, M. Paesmans, T. Berghmans, and M. Dusart The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 92 2005 131 139
14. W. Pao, T.Y. Wang, G.J. Riely, V.A. Miller, Q. Pan, and M. Ladanyi KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
15. T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, and C. Butts Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597
16. N. Girard, C. Deshpande, C.G. Azzoli, V. Rusch, W. Travis, and M. Ladanyi Use of EGFR/KRAS mutation yesting to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines Chest 137 2010 46 52
17. M. Ladanyi, and W. Pao Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond Mod Pathol 21 Suppl 2 2008 S16 S22
18. Q. Pan, W. Pao, and M. Ladanyi Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas J Mol Diagn 7 2005 396 403
19. C.I. Henschke, R. Yip, and O.S. Miettinen Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer JAMA 296 2006 180 184
20. D.G. Pfister, D.H. Johnson, C.G. Azzoli, W. Sause, T.J. Smith, and S. Baker Jr. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
21. K.M. Pisters, W.K. Evans, C.G. Azzoli, M.G. Kris, C.A. Smith, and C.E. Desch Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline J Clin Oncol 25 2007 5506 5518
22. J.P. Pignon, H. Tribodet, G.V. Scagliotti, J.Y. Douillard, F.A. Shepherd, and R.J. Stephens Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 2008 3552 3559
23. K.R. Shen, B.F. Meyers, J.M. Larner, and D.R. Jones Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 132 3 Suppl 2007 290S 305S
24. N. Martini, and M.R. Melamed Multiple primary lung cancers J Thorac Cardiovasc Surg 70 1975 606 612
25. Y.Y. Janjigian, B.J. Park, M.G. Kris, V.A. Miller, G.J. Riely, and J. Zheng Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations J Clin Oncol 27 suppl 2009 7523
26. S.P. D'Angelo, Y.Y. Janjigian, M.G. Kris, W. Pao, G.J. Riely, and J. Marks Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma J Clin Oncol 28 Suppl 2010 7011
27. Y. Lu, D. Bellgrau, L.D. Dwyer-Nield, A.M. Malkinson, R.C. Duke, and T.C. Rodell Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy Cancer Res 64 2004 5084 5088
28. M. Soda, Y.L. Choi, M. Enomoto, S. Takada, Y. Yamashita, and S. Ishikawa Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566